Abstract
SESSION TITLE: Diffuse Lung Disease SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/10/2018 01:00 pm - 02:00 pm PURPOSE: Many predictive risk factors of idiopathic pulmonary fibrosis (IPF/ UIP) such as FVC, DLCO, and 6-MWT showed low accuracy in recent clinical trials... Aims: to evaluate the prognostic value of the New York Heart Association index (NYHA) compared to high resolution CT, somatostatin receptor scintigraphy (octreoscan), and echocardiography METHODS: A prospective study population of 128 patients, IPF = 59, NSIP = 19, granulomatous diseases, such as sarcoidosis, Wegener granulomatosis, alveolitis, = 50 were enrolled respectively. The diagnosis of all patients was confirmed histologically. RESULTS: Median survival was 89.3 months (7.4 years) and 79.4 percent of patients were alive at 3 years after diagnosis with a poorer survival rate among UIP patients. Strong correlation was found with age (p<0.001), CT-score, octreoscan between all UIP patients with respect to NSIP and granulomatous diseases. No deaths were observed among patients with NYHA index and prognosis was progressively worse with increased index (LRT p-value <0.001). Among patients with UIP, NYHA was confirmed to be a performing prognostic factor, as survival of patients with moderate levels was lower than that observed in lower NYHA levels (p<0.01) Indeed, age and NYHA were independent prognostic factors (LLR test p-value <0.001) . CONCLUSIONS: The NYHA index is confirmed to be a reliable and important prognostic factor when observing the significant difference in survival rates among the different NYHA levels, and when confirming for the histological pattern of UIP. CLINICAL IMPLICATIONS: Following our findings we strongly recommend the use of NYHA as prognostic factor of IPF including graulomatous lung diseases. DISCLOSURES: no disclosure on file for Giovanni Bottino; No relevant relationships by Roberto CARBONE, source=Web Response no disclosure on file for Assaf Monselise; no disclosure on file for Paolo Paredi
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
